NDA 206500 · Tersera
Varubi
Rolapitant Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Aug 19, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Sep 1, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
3 Phase 3, 0 recruiting
FAERS reports
539
418 serious, 164 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 8, 2026.
VARUBI ® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. ( 1 )
Mechanism: Rolapitant is a selective and competitive antagonist of human substance P/NK1 receptors. Rolapitant does not have significant affinity for the NK2 or NK3 receptors or for a battery of other receptors, transporters, enzymes and ion channels. Rolapitant is also active in animal models of chemotherapy-induced emesis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VARUBI · ROLAPITANT HYDROCHLORIDE EQ 90MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rolapitant" as an intervention, any sponsor and status, largest first.
- Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic ChemotherapyPivotal-lookingCompleted
Tesaro, Inc.GSK (GSK)
NCT01500226 · 1,369 participants · Start Feb 2012 · Primary completion Feb 2014
Drug: Rolapitant; Granisetron and 2 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Waltham, Massachusetts
- A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00539721 · 619 participants · Start Oct 2007 · Primary completion Jul 2008
Drug: Rolapitant Dose 1; Rolapitant Dose 2 and 4 more · For: Postoperative Nausea and Vomiting
- Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyPivotal-lookingCompleted
Tesaro, Inc.GSK (GSK)
NCT01500213 · 555 participants · Start Feb 2012 · Primary completion Mar 2014
Drug: Rolapitant; Granisetron and 2 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Waltham, Massachusetts
- Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyPivotal-lookingCompleted
Tesaro, Inc.GSK (GSK)
NCT01499849 · 532 participants · Start Feb 2012 · Primary completion May 2014
Drug: Rolapitant; Granisetron and 2 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Waltham, Massachusetts
- A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)Pivotal-lookingCompleted
Schering-PloughMerck & Co. (MRK)
NCT00394966 · 450 participants (planned) · Start Sep 2006 · Primary completion Mar 2008
Drug: SCH 619734 Dose 1; SCH 619734 Dose 2 and 3 more · For: Nausea; Vomiting
- A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and PalonosetronNot yet recruiting
Henan Cancer HospitalGovernment (non-federal)
NCT07442890 · 238 participants (planned) · Start Apr 30, 2026 · Primary completion Apr 30, 2028
Drug: Rolapitant Palonosetron; Dexamethasone and 1 more · For: Lung Cancer
- An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous RolapitantPivotal-lookingCompleted
Tesaro, Inc.GSK (GSK)
NCT02285647 · 138 participants · Start Sep 2014 · Primary completion Apr 2015
Drug: Rolapitant - Oral; Rolapitant - IV · For: Chemotherapy-induced Nausea and Vomiting
Sites: Baltimore, Maryland
Tesaro, Inc.GSK (GSK)
NCT02434861 · 102 participants · Start May 2015 · Primary completion Jul 2015
Drug: Rolapitant; Digoxin and 2 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Baltimore, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death143
- nausea79
- fatigue51
- infusion related reaction40
- dyspnoea34
- decreased appetite33
- flushing32
- diarrhoea30
- thrombocytopenia29
- dehydration22
- vomiting22
- chest discomfort21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 17 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 94 |
| 2017 | 111 |
| 2018 | 96 |
| 2019 | 60 |
| 2020 | 116 |
| 2021 | 18 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Varubi (Rolapitant HCl)
2024 spending
$533K
Beneficiaries
167
527 claims
Per beneficiary
$3,191
$321.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $738,837 |
| 2021 | $901,960 |
| 2022 | $820,442 |
| 2023 | $497,575 |
| 2024 | $532,977 |
Part B: Varubi (Rolapitant HCL) · HCPCS J8670
2024 spending
$9K
Beneficiaries
18
32 claims
Per beneficiary
$498
2024 ASP limit $1.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $7,128 |
| 2023 | $0 |
| 2024 | $8,967 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, et al. · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Wang X, Wang J, Arora S, et al. · J Clin Pharmacol 2019 · Clinical Trial, Phase I, Randomized Controlled Trial
- Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V, Adams A, Haque M, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
Wang J, Wang X, Zhang ZY, et al. · J Clin Pharmacol 2018 · Clinical Trial, Phase I, Multicenter Study
- Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting.
Wang X, Wang J, Zhang ZY, et al. · Clin Pharmacol Drug Dev 2019 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting.
Ahmed H, Hammad AM, Abushouk AI, et al. · Curr Probl Cancer 2018 · Meta-Analysis, Systematic Review
Sponsor: Tersera
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.